AACR 2024 | A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies

Pau Abrisqueta, MD, PhD, Vall d´Hebron University Hospital, Barcelona, Spain, discusses the results of the first-in-human Phase I study (NCT04240704) investigating the safety and efficacy of JBH492, an anti-CC chemokine receptor 7 (anti-CCR7) antibody-drug conjugate (ADC), in patients with relapsed/refractory (R/R) lymphoid malignancies. In this dose escalation study, 25 patients were enrolled, and five dose levels were evaluated. The most common adverse events included thrombocytopenia, anemia, and elevated levels of alanine transaminase (ALT) and aspartate transaminase (AST), and dose reduction was most commonly required due to ocular toxicity. Dr Abrisqueta highlights that CCR7 presents a promising novel target due to being well-tolerated and showing preliminary signs of clinical efficacy. Unfortunately, a correlation between CCR7 expression and response could not be established due to the limited sample size. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.